Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archdermatol.2009.192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC.
Eur J Radiol
January 2025
Department of Radiology, West China Hospital Sichuan University Chengdu Sichuan China. Electronic address:
Purpose: To develop and validate an MRI-based model for predicting postoperative early (≤2 years) recurrence-free survival (RFS) in patients receiving upfront surgical resection (SR) for beyond Milan hepatocellular carcinoma (HCC) and to assess the model's performance in separate patients receiving neoadjuvant therapy for similar-stage tumors.
Method: This single-center retrospective study included consecutive patients with resectable BCLC A/B beyond Milan HCC undergoing upfront SR or neoadjuvant therapy. All images were independently evaluated by three blinded radiologists.
Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Importance: Nelonemdaz selectively antagonizes the 2B subunit of the N-methyl-d-aspartate glutamate receptor and scavenges free radical species.
Objective: To evaluate whether nelonemdaz enhances the clinical outcomes of patients with acute ischemic stroke undergoing emergent reperfusion therapy.
Design, Setting, And Participants: This multicenter double-blind placebo-controlled randomized phase 3 trial (December 25, 2021, to June 30, 2023, in South Korea) recruited patients with acute ischemic stroke who met the following criteria: National Institutes of Health Stroke Scale score greater than or equal to 8, Alberta Stroke Program Early Computed Tomography score greater than or equal to 4, and endovascular thrombectomy within 12 hours after stroke onset.
Chinese herbal formula Tongxie Yaofang granules for diarrhoea-predominant irritable bowel syndrome: a randomised, double-blind, placebo-controlled, phase II trial.
BMJ Open
January 2025
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
Objectives: To assess the therapeutic effects and safety of Tongxie Yaofang (TXYF) granules vs placebo as an alternative treatment for diarrhoea-predominant irritable bowel syndrome (IBS-D). We hypothesised that TXYF would improve clinical responses among patients with IBS-D.
Design: A randomised, double-blind, placebo-controlled, phase II, superiority trial.
No gender differences in attraction to young partners: A study of 4500 blind dates.
Proc Natl Acad Sci U S A
February 2025
Tawkify, Inc., Wilmington, DE 19804.
In mixed-gender couples, men are older than women on average. Scholars and laypeople presume that this arrangement reflects mirrored preferences such that men desire younger partners and women desire older partners. Nevertheless, relevant published data on in-person romantic evaluations-that is, studies where adults interact in person and report their initial attraction to each other-are nearly nonexistent.
View Article and Find Full Text PDFRandomized controlled trial on the efficacy of forest walking compared to urban walking in enhancing mucosal immunity.
Sci Rep
January 2025
Le Verseau Inc., Tokyo, 156-0051, Japan.
Scientific research on forest therapy's preventive medical and mental health effects has advanced, but the need for clear evidence for practical applications remains. We conducted an unblinded randomized controlled trial involving healthy men aged 40-70 to compare the physiological and psychological effects of forest and urban walking. Eighty-four participants were randomly assigned to either the forest or urban group, with 78 completing 90-min walks and analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!